Neuroscience Based Nomenclature is an initiative by a number of prestigious organizations supporting research in neuroscience and psychiatry to change the way that we talk about psychotropic / psychiatric medications. Why this might be useful is illustrated by conversations that are likely familiar to all psychiatrists… A severely depressed patient with bipolar 1 is discussing her need for a change …
Depression Biology and Treatment
New research on depression biology and treatment highlights the rapid increase in knowledge in this area in the last decade. In this post we will summarize some of these research findings briefly. This brief tour will take us to a newly discovered protein that may be a vital link between stress and depression. A genome wide search for changes associated …
Significance of Events and Serotonin 2A
Making sense of the constant bombardment of information and sensory experience that all of us face requires the ability to determine the significance of events, and an elegant study suggests that the serotonin 2A receptor plays a critical role in determining significance. Many psychiatric conditions and human experiences are associated with the misattribution of meaning to events. For example, delusional disorder …
Oxytocin and Spirituality
Oxytocin is a fascinating neurohormone which has been linked to parent-child bonding as well as romantic love, and to darker emotions such as the rejection of “foreigners”. A recent article suggests that it may also be an important factor in the development of spirituality. Joel Yager, writing in the NEJM Journal Watch Psychiatry, summarizes the study this way: Investigators enrolled …
Depression, Anhedonia, Glutamate, and Inflammation
That depression may be linked to alterations in glutamate circuits is suggested by the observation that ketamine (which is an NMDA glutamate receptor antagonist) may rapidly reverse depression in some patients. Depression has also been found to be associated in some people with various markers for inflammation (c reactive protein, tumor necrosis factor, interleukin 1 beta, and interleukin 6). As …
Depression Therapeutics and Mechanisms
The September 15, 2016 edition of Biological Psychiatry is devoted to updates in the area of psychobiology that relate to depression and its treatment. In this blog post I will summarize some of those studies to give you a sense of what is going on in the field. Some of these studies may not be replicated in follow-up research, but some …
A New Model of Anxiety and Fear
We often tell our patients that the treatment of anxiety is primarily through psychotherapy, in contrast to the treatment of mood disorders which is often based on medications or brain stimulation. In fact, it is one of the more frustrating aspects of psychiatry that there has been so little progress in terms of the biological treatments of anxiety and fear …
Why SSRIs May Increase Anxiety Short Term
SSRIs are among the most commonly prescribed medications for chronic anxiety, but not infrequently these medications may be associated with a short term increase in symptoms that precedes the long term benefit. In an elegant series of studies published online in late August 2016 in the premier scientific journal, Nature, researchers from the NIH and the University of North Carolina at …
Genesight – Genetic Testing to Predict Medication Response
We have been using the Genecept Assay from Genomind for several years to help guide treatment selection in patients with either unusually high rates of side effects from medications or those who have failed multiple trials of medications. Although the test can be expensive, costing anywhere from a couple of hundred dollars to five hundred dollars or more, it is our experience …
Antidepressants Alter Gene Expression
An interesting study looked at similarities and differences in the effects of two medications that have anti-depressant effects and yet are extremely different in terms of how they work: ketamine and imipramine (a tricyclic antidepressant). This industry supported study looked at the effects of these two agents on a reward circuit (involving the prefrontal cortex (PFC), nucleus accumbens, hippocampus, and amygdala – …